Current status:

Up 66.24% for a paper profit of $140,134

Current share price $3.31

Change over the last month $3,188

Current mood: I’m once again asking you for $30m

After 8 months of sideways trading I’m convinced I may have accidentally joined a cult. So much hype that we’re the chosen few investors who know that Zantrene™ is going to change the cancer world and on r̶a̶p̶t̶u̶r̶e̶ buyout day we’ll all be s̶a̶v̶e̶d̶ rich.

I kid, of course, as I’m still firmly bullish on RAC, but christ almighty is it frustrating seeing good news drop and the share price do sweet fuck all in response when other stocks go up 30% every time they release an update that one of the directors sneezed.

Initially purchased 85,000 RAC on 15/01/21 and topped up thereafter for a total of $219k invested at an average buy price of $1.99. Holding until at least $20/share which will net a paper profit of $2m in tendies.

Please note it's a speculative bio-tech stock and may yet prove utterly useless, but here’s why I’m bullish

As a company RAC are executing a three pillar strategy over the next 24-36 months with a steady stream of trial results coming through over that time. They've made it blatantly clear the aim is to get picked up by big pharma at the end of their phase 2 trials and that they're looking for maximum shareholder value™ in the process, as the board are significant shareholders.

RAC own the patent for a drug called Zantrene (formerly Bisantrene), which is a a potent FTO (fat mass and obesity) inhibitor. Preliminary preclinical, phase 1 and phase 2 trials have shown FTO inhibition to be the key to slowing the growth or killing cancer in up to 15% of patients across 27 different types of cancers.

Only a handful of drugs are known to inhibit FTO, and RAC is both one of the most potent and by miles the most advanced of any drug being explored in the space. This article in the world’s worst newspaper provides a pretty good overview of what Zantrene is capable of.

RAC advised during their AGM presentation that the FTO market alone is worth US$120b a year, which is exciting news if you’re at the pointy end of the effectiveness and by far the closest to getting approved for production.

RAC also dropped their heart safety pre-clinical data in November and the results are good news for cancer suffers. Typically when you receive treatment with anthracyclines (anti-cancer drugs) it fucks up your heart, more than half of patients end up with heart disease within 6 years of finishing treatment. When used in conjunction with Zantrene pre-clinical results have shown there’s no heart damage, and existing heart damage can even be reversed. RAC have stated this is a “multi-billion dollar addressable market" How sweet is that.

There’s a few more strings in the bow, but the other bit that I’m excited about is the possible enhancements of Zantrene to make it more patient friendly and effective when used in conjunction with other anti-cancer drugs such as anti-PD1 inhibitors. Currently most cancer patients have to suffer a shitty two hour IV process when receiving treatment, which makes it difficult and more costly to administer. RAC are working on an oral formulation which would make this process simpler for cancer patients.

Now the dense stuff, which shows how I do my DD for a stock and stay across everything that happens, even when all in.

RAC’s 11/21 AGM presentation

Dr Tendies 11/21 chat with ASX Investor

A slightly outdated rundown of RAC by an investment company

Nerds rejoice, a rundown on the science behind FTO

For those of you who can’t read good, and want learn to do other stuff good too here’s a video breakdown on FTO.

Or if you’d like some counterpoints there’s some robust discussion here and here, a dumpster fire of a Reddit thread which presents some counterarguments from oncology doctors it can be found here and another one here here. I’ve also noted what I identify to be the main risks here.

Please understand that this is a small cap biotech stock, meaning its share price is highly volatile, there’s no guarantees of success, and setbacks can and do occur along the way. I’ve YOLO’d into it because I have a high risk appetite and risk tolerance, but very few people share a similar investing strategy.

Finally for those who want confirmation this stock will be a winner, this video is proof.

Once again it's a speculative bio-tech stock and may yet prove utterly useless.

Just imagine how angry your wife’s boyfriend would be if you lost your allowance investing in a bio-tech stock knowing that biotech stocks typically have a binary outcome.

Also to pre-empt a couple of questions regarding the cap raise for $29m

Are you buying into the share purchase plan announced at the AGM?

Yes, I've purchased my full allotment of 10,000 shares for $30,000, expect to see that added to the tally in the next update.

I thought you were already all in, why would you lie to us like that?

It’s not my money